Cohance Lifesciences Ltd logo

Cohance Lifesciences Ltd

COHANCE NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹17,699 Cr
Volatility
Moderate
P/E Ratio
163.74
EBITDA
₹398 Cr
Return on Equity
14.38%
Debt to Equity
0.1
Book Value
₹102.23
EPS
₹9.45
52W High
₹1,038.9
52W Low
₹266.7

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Cohance Lifesciences Ltd insights

56 extracted metrics + investor summaries across FY18–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Weaknesses

6
  • Stock is trading at 4.35 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 10.7% over last 3 years.
  • Promoters have pledged 94.6% of their holding.
  • Debtor days have increased from 80.9 to 110 days.
  • Working capital days have increased from 122 days to 175 days

Growth Rate

Revenue Growth
80.60% ↗
Net Income Growth
-51.98% ↗
Cash Flow Change
-19.62% ↘
ROE
-1.78% ↗
ROCE
-30.56% ↗
EBITDA Margin (Avg.)
-50.01% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk high

Cohance Lifesciences trades at a market cap of ~₹16,997 Cr with a PE of 290.5x, reflecting a sharp TTM profit decline of 77%. The company has delivered 18-19% sales CAGR over 3-5 years but faces severe near-term headwinds including deteriorating working capital, collapsing profitability, and 94.6% promoter pledge.

Bull Case 7
  • Compounded sales growth of 19% over 3 years and 18% over 5 years indicates a strong historical revenue trajectory in the healthcare/CDMO space
  • Healthcare and lifesciences sector offers structural long-term tailwinds from global outsourcing trends and patent cliffs benefiting Indian API/CDMO players
  • Market cap of ₹16,997 Cr suggests institutional interest and scale in the contract manufacturing and intermediates business
  • Dividend yield of 1.35% provides some income cushion despite the stock's 52% decline over the past year
  • 5-year average ROE of 16% demonstrates the business historically earned respectable returns on shareholder equity before the recent downturn
  • Price-to-book of 4.35x, while elevated, is lower than some peers in the specialty chemicals/pharma CDMO segment, and the 52% stock price correction has compressed valuations from prior highs
  • 3-year compounded sales growth of 19% significantly outpaces the TTM decline of -20%, suggesting the revenue drop may be cyclical rather than structural
Bear Case 8
  • Promoters have pledged 94.6% of their holding, creating extreme risk of forced selling or loss of control in a further downturn
  • TTM profit has collapsed by 77%, driving the PE ratio to an unsustainable 290.5x and signaling severe earnings stress
  • Stock price has declined 52% over the past 1 year, reflecting significant erosion of investor confidence
  • Debtor days have increased from 80.9 to 110 days, indicating deteriorating collection efficiency and potential customer credit issues
  • Working capital days have expanded from 122 to 175 days, tying up significantly more capital in operations and pressuring cash flows
  • Last year ROE fell to just 7% versus the 5-year average of 16%, a more than 50% decline in return efficiency
  • 3-year compounded profit CAGR is -21% and 5-year is -11%, showing a sustained multi-year erosion in profitability despite top-line growth
  • TTM sales declined 20% year-over-year, raising concerns about order book visibility and client concentration risk

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 19h ago
Headwinds 2
  • 97% profit drop in Q1FY27 Aug 5

    Standalone net profit crashed 97.3% to ₹14 crore in Q1FY27 due to shipment phasing and lower CDMO contribution. Consolidated results show a loss of ₹452 crore.

  • US FDA Form 483 five observations Aug 5

    Hyderabad facility received US FDA Form 483 with five observations following a regulatory inspection. Specific nature of observations not disclosed; company must respond with corrective measures.

Neutral 2
  • Q4FY26 conference call recording available Aug 5

    Audio recording of the Q4FY26 conference call held on August 5, 2026 is available on the company website for investor access.

  • Q1 FY27 earnings call scheduled Jul 23

    Conference call to discuss unaudited Q1 FY27 results was scheduled for August 5, 2026 at 6:30 PM IST.

TL;DR: Cohance Lifesciences faces a difficult quarter with a 97.3% standalone profit decline and a consolidated loss of ₹452 crore, compounded by a US FDA Form 483 with five observations at its Hyderabad facility. There are no positive catalysts visible in recent news. The trend is clearly deteriorating, and investors should watch for the company's FDA response and whether CDMO revenues recover in coming quarters.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
348
231
220
253
488
604
676
840
549
556
545
619
422
Expenses
181
133
154
180
363
398
439
611
437
435
449
520
421
Operating Profit
167
98
66
73
125
205
237
229
112
121
95
99
1
OPM %
48%
42%
30%
29%
26%
34%
35%
27%
20%
22%
18%
16%
0.3%
Other Income
11
20
14
17
19
16
22
-4
6
16
1
-18
12
Interest
1
0
2
2
10
10
11
10
10
9
9
9
7
Depreciation
13
12
13
17
31
38
44
54
45
44
47
51
50
PBT
164
105
65
71
103
174
205
161
63
84
41
20
-43
Tax %
26%
25%
29%
25%
27%
21%
25%
27%
26%
21%
29%
58%
5%
Net Profit
121
80
47
53
75
138
153
117
46
66
29
8
-45
EPS in Rs
4.74
3.13
1.84
2.1
2.96
5.44
6.01
4.73
1.28
1.94
0.96
0.51
-0.63
Figures in ₹ Crores

Profit & Loss

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
378
834
1,010
1,320
1,340
1,051
1,198
2,269
2,142
Expenses
206
449
567
738
766
645
822
1,842
1,825
Operating Profit
172
385
443
582
574
406
375
427
316
OPM %
45%
46%
44%
44%
43%
39%
31%
19%
15%
Other Income
1
66
68
133
46
62
58
5
11
Interest
3
23
12
9
13
7
12
37
34
Depreciation
12
24
32
39
48
55
77
187
192
PBT
158
405
468
668
560
406
344
207
101
Tax %
31%
22%
23%
32%
27%
26%
23%
27%
—
Net Profit
109
317
362
454
411
300
265
150
59
EPS in Rs
—
12.45
14.23
17.83
16.16
11.8
10.52
4.68
2.78
Div. Payout %
0%
20%
14%
28%
37%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0
13
25
25
25
25
25
38
Reserves
578
832
1,155
1,502
1,710
2,025
1,671
3,873
Borrowings
83
186
143
97
70
65
279
400
Other Liabilities
123
142
151
205
160
138
1,056
1,418
Total Liabilities
783
1,173
1,474
1,830
1,966
2,254
3,031
5,730
Fixed Assets
271
357
441
534
663
670
1,713
3,373
CWIP
111
102
96
30
165
179
256
173
Investments
7
338
542
598
536
904
337
529
Other Assets
394
376
395
667
601
501
725
1,655
Total Assets
783
1,173
1,474
1,830
1,966
2,254
3,031
5,730
Figures in ₹ Crores

Cash Flow

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
50
407
383
330
457
358
288
368
Investing
-65
-413
-311
-136
-195
-362
-253
-255
Financing
26
7
-76
-156
-242
-14
3
-165
Net Cash Flow
11
1
-5
37
20
-18
38
-51
Free Cash Flow
-6
304
272
255
171
307
132
169
CFO/OP
49
128
111
88
105
115
99
102
Figures in ₹ Crores

Ratios

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
142
51
37
65
30
46
87
110
Inventory Days
556
278
243
259
279
268
199
310
Days Payable
190
113
100
97
63
49
96
157
Cash Conversion Cycle
509
217
180
228
247
265
190
263
Working Capital Days
205
64
56
108
99
115
74
175
ROCE %
—
50%
40%
41%
32%
19%
15%
8%

Shareholding Pattern

As of Jun 2026
Promoters 57.49%
DIIs 20.09%
Others 8.21%
Public 7.71%
FIIs 6.50%
Government 0.01%
Total 100.01%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025May 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
50.10%
50.10%
50.10%
50.10%
50.10%
66.41%
66.41%
57.49%
57.49%
57.49%
57.49%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
10.01%
10.14%
9.54%
9.80%
10.70%
10.84%
11.05%
7.38%
7.23%
6.51%
6.02%
5.59%
6.50%
DIIs
4.30%
4.47%
4.94%
5.24%
5.91%
6.32%
10.52%
11.35%
11.43%
9.23%
14.14%
15.94%
17.24%
17.42%
16.94%
16.68%
16.60%
11.02%
11.40%
20.82%
21.57%
21.79%
20.09%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
Public
20.87%
19.86%
19.21%
18.38%
17.07%
16.86%
14.69%
14.01%
12.76%
12.80%
11.76%
10.87%
10.51%
10.08%
9.75%
9.81%
9.68%
6.63%
6.40%
6.42%
6.76%
7.04%
7.71%
Others
14.84%
15.68%
15.86%
16.38%
17.02%
16.82%
14.78%
14.64%
15.81%
17.97%
4.08%
3.04%
12.59%
12.59%
12.50%
12.56%
12.55%
8.55%
8.55%
8.75%
8.16%
8.08%
8.21%
No. of Shareholders
75,207
92,534
96,532
86,447
85,725
86,088
82,577
79,412
72,885
72,167
73,715
70,052
68,932
65,777
69,337
84,210
86,325
88,658
80,910
75,284
81,877
85,230
99,149

Documents

Frequently Asked Questions about Cohance Lifesciences Ltd

What does Cohance Lifesciences Ltd do?
Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while...
Where is Cohance Lifesciences Ltd (COHANCE) listed?
Cohance Lifesciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: COHANCE and BSE: 543064. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Cohance Lifesciences Ltd belong to?
Cohance Lifesciences Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd has a market capitalisation of approximately ₹17699.47 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Cohance Lifesciences Ltd?
The Price-to-Earnings (PE) ratio of Cohance Lifesciences Ltd is 163.74. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Cohance Lifesciences Ltd?
Over the past 52 weeks, Cohance Lifesciences Ltd has traded between a low of ₹266.7 and a high of ₹1,038.9. This range helps investors understand the stock's price volatility and recent trading levels.
Does Cohance Lifesciences Ltd pay dividends?
Yes, Cohance Lifesciences Ltd has a dividend yield of 1.35%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd has a Return on Equity (ROE) of 14.38%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Cohance Lifesciences Ltd on Tapetide?
On Tapetide, you can view Cohance Lifesciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules.[1][2]

Website cohance.com
CEO Mr. Vivek Sharma CPA
Employees 1,212
Listed 2020-03-09
Face Value ₹ 1
Issued Size 38,25,67,140

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List